Patient subgroups and potential risk factors in systemic sclerosis: Is there a possibility of an early diagnosis?

International Journal of Clinical Rheumatology

Volumn 5, Issue 5, 2010, Pages 555-564

  Bellando Randone, Silvia ^a   Guiducci, Serena ^a   Matucci Cerinic, Marco ^a  

^a Division of Rheumatology   (Italy)

Author keywords

complications; early diagnosis; risk factors; systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; CENTROMERE ANTIBODY;

DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; FIBROSIS; GASTROINTESTINAL DISEASE; HUMAN; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; ORGAN INJURY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RAYNAUD PHENOMENON; REVIEW; RISK FACTOR; SUDDEN DEATH; SYSTEMIC SCLEROSIS; ULCER; VASCULAR DISEASE;

EID: 77958029836     PISSN: 17584272     EISSN: None     Source Type: Journal    
DOI: 10.2217/ijr.10.53     Document Type: Review

References (82)

1. Chiffolt H, Fautrel B, Sordet C, Chateleu E, Sibilia J: Incidence and prevalence of systemic sclerosis: A systemic literature review. Semin. Arhritis Rheum. 37, 223-235 (2008).
2. Mayes MD: Scleroderma epidemiology. Rheum. Dis. Clin. North Am. 29, 239-254 (2003).
3. Le Guern V, Mahr A, Mouthon L, Jeanneret D, Cazon M, Guillevin L: Prevalence of systemic sclerosis in a French multi-ethnic cohort. Rheumatology 43, 1129-1137 (2004).
4. Mayes MD, Lacey JV, Beebe-Dimmer J et al.: Prevalence, incidence, survival and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum.48, 2246-2255 (2003).
5. Varga J, Abraham D: Systemic sclerosis: A prototypic multisystem fibrotic disorder. J. Clin. Invest. 117, 557-567 (2007).
6. Matucci-Cerinic M, Steen V, Nash P, Hachulla E: The complexity of managing systemic sclerosis: Screening and diagnosis. Rheumatology 48, iii8-iii13 (2009).
7. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma).Arthritis Rheum. 23, 581-590 (1980).
8. LeRoy EC, Medsger TA Jr: Criteria for the classification of early systemic sclerosis. J. Rheumatol. 28, 1573-1576 (2001).
9. Koenig M, Joyal F, Fritzler MJ et al.: Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 58, 3902-3912 (2008).
10. LeRoy EC, Black C, Fleischmajer R et al.: Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J. Rheumatol. 15, 202-205 (1988).
11. Lonzetti LS, Joyal F, Raynauld JP et al.: Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: Addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum. 44, 735-736 (2001).
12. Walker UA, Tyndall A, Czirják L et al.: Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR scleroderma trials and research group database. Ann. Rheum. Dis. 66, 754-763 (2007).
13. Hudson M, Taillefer S, Steele R et al.: Improving the sensitivity of the American College of Rheumatology classification criteria for systemic sclerosis. Clin. Exp. Rheumatol. 25, 754-757 (2007).
14. Del Rosso A, Boldrini M, D'Agostino D et al.: Health-related quality of life in systemic sclerosis as measured by the Short Form 36: Relationship with clinical and biologic markers. Arthritis Rheum. 51(3), 475-481 (2004).
15. Valentini G, Matucci Carinic M: Disease specific quality indicators, guidelines and outcome measures in scleroderma.Clin. Exp. Rheumatol. 25, 159-162 (2007).
16. Cutolo M, Grassi W, Matucci Cerinic M: Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum.48, 3023-3030 (2003).
17. Fine LG, Denton CP, Korn J,de Crombrugghe B, Black CM: Systemic sclerosis: Current pathogenetic concepts and future prospects for targeted therapies. Lancet 3(47), 1453-1458 (1996).
18. LeRoy EC, Maricq HR, Kahaleh BM: Undifferentiated connective tissue syndromes. Arthritis Rheum. 23, 341-343 (1980).
19. Lundberg IE: The prognosis of MCTD. Rheum. Dis. Clin. North Am. 31, 535-547 (2005).
20. Matucci-Cerinic M, Allanore Y, Czirják L et al.: The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy.Ann. Rheum. Dis. 68, 1377-1380 (2009).
21. Hudson M, Thombs B, Baron M: Time to diagnosis in systemic sclerosis: Is gender a factor? Arthritis Rheum. 56, 487-489 (2007).
22. Kowal-Bielecka O, Landewé R, Avouac J et al.: EULAR/EUSTAR recommendations for the treatment of systemic sclerosis.Ann. Rheum. Dis. 68(5), 620-628 (2009).
23. Denton CP, Black CM, Abraham DJ: Mechanisms and consequences of fibrosis in systemic sclerosis. Nat. Clin. Pract. Rheumatol. 2, 134-144 (2006).
24. Hummers L, Wigley F: Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. Rheum. Dis. Clin. North Am. 29, 293-313 (2003).
25. Hachulla E, Clerson P, Launay D et al.: Natural history of ischemic digital ulcers in systemic sclerosis: Single-center retrospective longitudinal study. J. Rheumatol. 34, 2423-2430 (2007).
26. Ingegnoli F, Boracchi P, Gualtierotti R et al.: Prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (Prognostic Index for Nailfold Capillaroscopic Examination). Arthritis Rheum. 58, 2174-2182 (2008).
27. Cutolo M, Matucci Cerinic M: Improving the sensitivity of the American College of Rheumatology classification criteria for systemic sclerosis. Clin. Exp. Rheumatol.25, 663-665 (2007).
28. Grassi W, de Angelis R: Capillaroscopy: Questions and answers. Clin. Rheumatol.26, 2009-2016 (2007).
29. Cutolo M, Sulli A, Secchi ME, Paolino S, Pizzorni C: Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases: A future tool for the analysis of microvascular heart involvement? Rheumatology (Oxford) 45(Suppl. 4), iv43-iv46 (2006).
30. Caramaschi P, Canestrini S, Martinelli N et al.: Scleroderma patients nailfold videocapillaroscopic patterns are associated with disease subset and disease severity. Rheumatology (Oxford) 46, 1566-1569 (2007).
31. Sebastiani M, Manfredi A, Colaci M et al.: Capillaroscopic skin ulcer risk index: A new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum. 61, 688-694 (2009).
32. Alivernini S, De Santis M, Tolusso B et al.: Skin ulcers in systemic sclerosis: Determinants of presence and predictive factors of healing. J. Am. Acad. Dermatol. 60(3), 426-435 (2009).
33. Sackner MA, Heinz ER, Steinberg AJ: The heart in scleroderma. Am. J. Cardiol.17, 542-559 (1966).
34. Clements PJ, Furst DE, Cabeen W et al.: The relationship arrhythmias and conduction disturbances to other manifestations of cardiopulmonary disease in progressive systemic sclerosis (PSS). Am. J. Med.71, 38-46 (1981).
35. Kostis JB, Seibold JR, Turkevich D et al.: Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am. J. Med.84, 1007-1015 (1988).
36. Follansbee WP: The cardiovascular manifestations of systemic sclerosis (scleroderma). Curr. Probl. Cardiol. 11(5), 241-298 (1986).
37. Bulkley BH, Klacsmann PG, Hutchins GM: Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: A clinicopathologic study of 9 patients with progressive systemic sclerosis. Am. Heart J. 95(5), 563-569 (1978).
38. Deswal A, Follansbee WP: Cardiac involvement in scleroderma. Rheum. Dis. Clin. North Am. 22(4), 841-860 (1996).
39. McWhorter JE 4th, LeRoy EC: Pericardial disease in scleroderma (systemic sclerosis). Am. J. Med. 57(4), 566-575 (1974).
40. Follansbee W, Curtiss E, Medsger TJ et al.: Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N. Engl. J. Med. 310, 142-148 (1984).
41. Kahan A, Devaux J, Amor B et al.: Pharmacodynamic effect of dipyridamole on thallium-201 myocardial perfusion in progressive systemic sclerosis with diffuse scleroderma. Ann. Rheum. Dis. 45(9), 718-725 (1986).
42. Kahan A, Devaux J, Amor B et al.: Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. N. Engl. J. Med. 314, 1397-1402 (1986).
43. Kahan A, Devaux J, Amor B et al.: The effect of captopril on thallium 201 myocardial perfusion in systemic sclerosis. Clin. Pharmacol. Ther. 47(4), 483-489 (1990).
44. Kahan A, Nitenberg A, Foult J et al.: Decreased coronary reserve in primary scleroderma myocardial disease.Arthritis Rheum. 28(6), 637-646 (1985).
45. Smith J, Clements P, Levisman J et al.: Echocardiographic features of progressive systemic sclerosis (PSS). Correlation with hemodynamic and postmortem studies. Am. J. Med. 66(1), 28-33 (1979).
46. Clements P: Systemic sclerosis (scleroderma) and related disorders: Clinical aspects. Baillieres Best Pract. Res. Clin. Rheumatol. 14(1), 1-16 (2000).
47. Champion HC: The heart in scleroderma. Rheum. Dis. Clin. North Am. 34(1), 181-190 (2008).
48. Hachulla AL, Launay D, Gaxotte V et al.: Cardiac magnetic resonance imaging in systemic sclerosis: A cross-sectional observational study of 52 patients. Ann. Rheum. Dis. 68(12), 1878-1884 (2009).
49. Kobayashi H, Yokoe I, Hirano M et al.: Cardiac magnetic resonance imaging with pharmacological stress perfusion and delayed enhancement in asymptomatic patients with systemic sclerosis. J. Rheumatol. 36, 106-112 (2009).
50. Bernardo P, Conforti ML,Bellando Randone S et al.: Implantable cardioverter defibrillator to prevent arrhythmic death in sclerodermic cardiomyopathy. J. Rheumatol. (2010) (In Press).
51. Steen VD, Medsger TA: Changes in causes of death in systemic sclerosis, 1972-2002.Ann. Rheum. Dis. 66, 940-944 (2007).
52. Wells AU, Steen V, Valentini G: Pulmonary complications: One of the most challenging complications of systemic sclerosis. Rheumatology 48, iii40-iii44 (2009).
53. Antonioua KM, Wells AU: Scleroderma lung disease: Evolving understanding in light of newer studies. Curr. Opin. Rheumatol.20, 686-691 (2008).
54. Steen VD: The lung in systemic sclerosis. J. Clin. Rheumatol. 11(1), 40-46 (2005).
55. Steen V: Predictors of end stage lung disease in systemic sclerosis. Ann. Rheum. Dis.62, 97-99 (2003).
56. Hoyles RK, Ellis RW, Wellsbury J et al.:A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum.54, 3962-3970 (2006).
57. Tashkin DP, Elashoff R, Clemets PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Eng. J. Med.354, 2655-2666 (2006).
58. Baltus JA, Boersma JW, Hartman AP, Vandenbroucke JP: The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide:a controlled retrospective follow-up.Ann. Rheum. Dis. 42, 368-373 (1983).
59. Bérezné A, Ranque B, Valeyre D et al.: Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: A retrospective multicenter open-label study. J. Rheumatol. 35(6), 1064-1072 (2008).
60. Hachulla E, Gressin V, Guillevin L et al.: Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis Rheum. 52, 3792-3800 (2005).
61. Condliffe R, Kiely DG, Peacock AJ et al.: Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am. J. Resp. Crit.Care Med. 179, 151-157 (2009).
62. Humbert M, Sitbon O, Chaouat A et al.: Pulmonary arterial hypertension in France: Results from a national registry. Am. J. Respir. Crit. Care Med. 173, 1023-1030 (2006).
63. MacGregor AJ, Canavan R, Knight C et al.: Pulmonary hypertension in systemic sclerosis: Risk factors for progression and consequences for survival. Rheumatology (Oxford)40, 453-459 (2001).
64. Mukerjee D, St George D, Coleiro B et al.: Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: Application of a registry approach.Ann. Rheum. Dis. 62, 1088-1093 (2003).
65. Distler O, Pignone A: Pulmonary arterial hypertension and rheumatic diseases: From diagnosis to treatment. Rheumatology (Oxford) 45(Suppl. 4), iv22-iv25 (2006).
66. Allanore Y, Borderie D, Avouac J et al.: High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum. 58(1), 284-291 (2008).
67. Gan CT, McCann MG, Marcus JT et al.: NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. Eur. Respir. J. 28, 1190-1194 (2006).
68. Blyth KG, Groenning BA, Mark PB et al.: NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur. Respir. J. 29, 737-744 (2007).
69. Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, Ueland T: N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic pre-capillary pulmonary hypertension. Am. J. Cardiol. 98, 525-529 (2006).
70. Hofstee HM, Vonk Noordegraaf A, Voskuyl AE et al.: Nailfold capillary density is associated with the presence and severity of pulmonary arterial hypertension in systemic sclerosis. Ann. Rheum. Dis. 68(2), 191-195 (2009).
71. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT); Galiè N, Hoeper MM, Humbert M et al.: Guidelines for the diagnosis and treatment of pulmonary hypertension. Right heart catheterism remains the golden standard for its diagnosis. Eur. Respir. J. 34(6), 1219-1263 (2009).
72. Barst RJ, Rubin LJ, Long WA et al.:A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 334, 296-302 (1996).
73. Channick RN, Simonneau G, Sitbon O et al.: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 358, 1119-1123 (2001). (Pubitemid 32971843)
74. Benza RL, Barst RJ, Galie N et al.: Sitaxsentan for the treatment of pulmonary arterial hypertension: A one year, prospective, open label, observation of outcome and survival. Chest 134, 775-782 (2008).
75. Galie N, Olschewski H, Oudiz RJ et al.: Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117, 3010-3019 (2008).
76. Galie N, Ghofrani HA, Torbicki A et al.: The Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group: Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353, 2148-2157 (2005).
77. Denton CP, Lapadula G, Mouthon L, Müller-Ladner U: Renal complications and scleroderma renal crisis. Rheumatology (Oxford) 48(Suppl. 3) iii32-iii35 (2009).
78. Nihtyanova SI, Parkers JC, Black CM, Bunn CC, Denton CP: A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis. Rheumatology (Oxford) 48(10), 1218-1221 (2009).
79. Clements PJ, Becvar R, Drosos AA, Ghattas L, Gabrielli A: Assessment of gastrointestinal involvement.Clin. Exp. Rheumatol. 21, S15-S18 (2003).
80. Ebert EC: Esophageal disease in scleroderma. J. Clin. Gastroenterol. 40(9), 769-775 (2006).
81. Koh CE, Young CJ, Wright CM, Byrne CM, Young JM: The internal anal sphincter in systemic sclerosis. Dis. Colon. Rectum 52(2), 315-318 (2009).
82. Avouac J, Fransen J, Walker U et al.: Defining preliminary criteria for the diagnosis of very early systemic sclerosis (VEDOSS): Results of a Delphi consensus study from EUSTAR. Ann. Rheum. Dis. (2010) (In Press).